参考文献
1.NCCN Clinical Practice Guidelines in Oncology（NCCN Guidelines）: Head and Neck Cancers Version 1.2019 — March 6, 2019.
2.American Joint Committee on Cancer（AJCC）Cancer Staging System（8th ed., 2017）.
3.Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018.CA Cancer J Clin 2018, 68: 7-30.Available at: https: //www.ncbi.nlm.nih.gov/pubmed/29313949.
4.Agalliu I, Gapstur S, Chen Z, et al.Associations of oral alpha-, beta-, and gamma-human papillomavirus types with risk of incident headand neck cancer.JAMA Oncol 2016.
5.Chen X, Gao L, Sturgis EM, et al.HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma.Ann Oncol 2017, 28: 1105-1110.
6.Schiffman M, Doorbar J, Wentzensen N, et al.Carcinogenic human papillomavirus infection.Nat Rev Dis Primers 2016, 2: 16086.
7.Sritippho T, Chotjumlong P, Iamaroon A.Roles of human papillomaviruses and p16 in oral cancer.Asian Pac J Cancer Prev 2015, 16: 6193-6200.
8.Chaturvedi AK, Graubard BI, Broutian T, et al.Effect of prophylactic human papillomavirus（HPV）vaccination on oral HPV infections among young adults in the United States.J Clin Oncol 2018, 36: 262-267.
9.Fakhry C, Zhang Q, Nguyen-Tan PF, et al.Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.J Clin Oncol 2014, 32: 3365-3373.
10.Fakhry C, Zhang Q, Nguyen-Tan PF, et al.Development and validation of nomograms predictive of overall and progression-free survivalin patients with oropharyngeal cancer.J Clin Oncol 2017, 35: 4057-4065.
11.Coordes A, Lenz K, Qian X, et al.Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status.Eur Arch Otorhinolaryngol 2016, 273: 2157-2169.
12.Gillison ML, Zhang Q, Jordan R, et al.Tobacco smoking and increased risk of death and progression for patients with p16-positiveand p16-negative oropharyngeal cancer.J Clin Oncol 2012, 30: 2102-2111.(https://www.daowen.com)
13.Vainshtein JM, Spector ME, Ibrahim M, et al.Matted nodes: High distant-metastasis risk anda potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer.Head Neck 2016, 38 Suppl 1: E805-814.
14.Wuthrick EJ, Zhang Q, Machtay M, et al.Institutionalcli nicaltrialaccrualvolumeandsurvival of patients with head and neck cancer.J Clin Oncol 2015, 33: 156-164.
15.David JM, Ho AS, Luu M, et al.Treatment at highvolume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.Cancer 2017, 123: 3933-3942.
16.Jabbour J, Milross C, Sundaresan P, et al.Education and support needs in patients with head andneckcancer: amulti-institutionalsurvey.Cancer 2017.
17.Smith BG, Hutcheson KA, Little LG, et al.Lymphedema outcomes in patients with head and neck cancer.Otolaryngol Head Neck Surg 2015, 152: 284-291.
18.Andersen BL, DeRubeis RJ, Berman BS, et al.Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation.J Clin Oncol 2014, 32: 1605-1619.
19.Arens C.Transoral treatment strategies for head and neck tumors.GMS Curr Top Otorhinolaryngol Head Neck Surg 2012, 11: Doc05.
20.Mehanna H, Wong WL, McConkey CC, et al.PET-CT surveillance versus neck dissection in advanced head and neck cancer.N Engl J Med 2016, 374: 1444-1454.
21.Van den Wyngaert T, Helsen N, Carp L, et al.Fluorodeoxyglucosepositron emission tomography/computed tomography afterconcurrent chemoradiotherapy in locallyadvanced head-and-neck squamous cell cancer: the ECLYPS Study.J Clin Oncol 2017, 35: 3458-3464.
22.Noronha V, Joshi A, Patil VM, et al.Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial.J Clin Oncol 2017: Jco2017749457.
23.Hasan Z, Dwivedi RC, Gunaratne DA, et al.Systematic review and meta-analysis of the complications of salvage total laryngectomy.Eur J Surg Oncol 2017, 43: 42-51.